Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Saturday
June 25, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SATURDAY, JUNE 25, 2022
Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety

Coronavirus chronicle

Hindustan Times
03 April, 2022, 11:00 am
Last modified: 03 April, 2022, 11:06 am

Related News

  • Monkeypox 'emergency' decision due from WHO sparks African criticism
  • Citizen's initiative declares monkeypox outbreak a 'pandemic', urges WHO action
  • Spain to begin monkeypox vaccination; global tally passes 1,000
  • WHO says Covid in N Korea likely 'getting worse, not better'
  • Outbreaks of diseases such as monkeypox becoming more frequent, warns WHO

Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety

On Saturday, the World Health Organisation (WHO) suspended the supply of Bharat Biotech's Covid vaccine, Covaxin, under the Covax facility, attributing it to deficiencies in manufacturing practices

Hindustan Times
03 April, 2022, 11:00 am
Last modified: 03 April, 2022, 11:06 am
Covaxin is produced by Bharat Biotech and is one of the vaccines being used in the nationwide inoculation drive. Photo :AFP via Hindustan Times
Covaxin is produced by Bharat Biotech and is one of the vaccines being used in the nationwide inoculation drive. Photo :AFP via Hindustan Times

Indian biotechnology company Bharat Biotech on Sunday issued a clarification over the suspension of its Covid-19 vaccine supplies by the World Health Organisation (WHO) through UN procurement agencies. The Hyderabad-based company said in a statement that there is "no impact on efficacy and safety of the Covid-19 vaccine COVAXIN".

"For the millions who have received COVAXIN, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine," the statement read. 

On Saturday, the UN health agency suspended the supply of Covaxin under the Covax facility, attributing it to deficiencies in manufacturing practices.

"The World Health Organisation (WHO) is today confirming the suspension of supply of Covaxin produced by Bharat (Biotech), through UN procurement agencies and recommending to countries that received the vaccine to take actions as appropriate," the UN agency said in a statement.

The suspension was announced following the WHO post-emergency use listing inspection conducted between March 14 -22. The inspection highlighted the need to conduct process and facility upgrades to address recently identified good manufacturing practice (GMP) deficiencies.

Bharat Biotech said it is slowing down the production of Covaxin for pending facility maintenance, process and facility optimization activities.

"As all existing facilities were repurposed for the manufacture of COVAXIN, with continuous production during the past year, to meet the public health emergency of Covid-19, these upgrades were due. Certain highly sophisticated equipment which was required to enhance the process stringency was unavailable during the Covid-19 pandemic. It has to be stressed that the quality of COVAXIN was never compromised at any point in time," it added.

As a result, there will be an interruption of the supply of Covaxin.

The company insisted that it is "diligently working to further improvements and upgrades to ensure that the production of COVAXIN continues to meet ever-increasing global regulatory requirements." 

"Since patient safety is the primary consideration for any new vaccine, there can be no compromises in meeting operational excellence objectives," it added.

The WHO also said that the risk assessment to date does not indicate a change in the risk-benefit ratio, with no issues related to the safety and efficacy of a vaccine.

'The data available to WHO, indicate the vaccine is effective and no safety concern exists. For continuation of vaccination with alternative sources of Covid19 vaccines countries should refer to the respective SAGE recommendation," the statement read.

COVAXIN / WHO / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • More than a bridge
    More than a bridge
  • Photo: Ariful Islam Mithu/TBS
    Bangladesh ready to celebrate Padma Bridge opening
  • Photo: Mumit M/TBS
    Padma Bridge is a testimony to courageous decisions and far-sighted leadership of Sheikh Hasina: India

MOST VIEWED

  • Anthony Fauci  Photo: Collected
    Top US medical expert Fauci says he is 'example' for Covid-19 vaccinations
  • An observation room in a Covid-19 vaccination center at a municipal hospital in Pune, in May 2021.
Photographer: Dhiraj Singh/Bloomberg
    India records 17,336 new coronavirus cases, a four-month high
  • Gaming machines are seen at the casino of MGM Cotai in Macau, China February 13, 2018/ Reuters
    Macau extends Covid shutdown of city, casinos stay open
  • Illustration: Collected
    Omicron sub variant dominant in Bangladesh since May : Report
  • Representational Image. Photo: Courtesy
    India’s new Covid cases top 13K-mark, biggest spike in over 120 days
  • Nearly 1 in 5 adults who had Covid have lingering symptoms - US study
    Nearly 1 in 5 adults who had Covid have lingering symptoms - US study

Related News

  • Monkeypox 'emergency' decision due from WHO sparks African criticism
  • Citizen's initiative declares monkeypox outbreak a 'pandemic', urges WHO action
  • Spain to begin monkeypox vaccination; global tally passes 1,000
  • WHO says Covid in N Korea likely 'getting worse, not better'
  • Outbreaks of diseases such as monkeypox becoming more frequent, warns WHO

Features

Our team full of hope and mettle, before we entered the disaster zone. PHOTO: SWAMIM AHMED

How we survived 4 days in Sunamganj flood

17h | Panorama
Photo: Bipul Sarker Sunny

Immigrants or refugees: Who really are the Maldoiyas?

18h | Features
Selim Raihan, executive director, Sanem. Photo: TBS

'To make full use of the bridge's connectivity in this region, we need Padma Plus'

19h | Interviews
‘We will keep our votes in pockets but won’t vote for the chairman-members’ 

‘We will keep our votes in pockets but won’t vote for the chairman-members’ 

1d | Panorama

More Videos from TBS

Messi means record, record means Messi

Messi means record, record means Messi

6h | Videos
Zovan, Safa to star in '24 Ghonta'

Zovan, Safa to star in '24 Ghonta'

6h | Videos
Modern rehabilitation centre for those affected by Padma Bridge land acquisition

Modern rehabilitation centre for those affected by Padma Bridge land acquisition

7h | Videos
What are included in Padma Bridge inauguration ceremony?

What are included in Padma Bridge inauguration ceremony?

9h | Videos

Most Read

1
Photo: Prime Minister's Office
Bangladesh

New investment in transports as Padma Bridge set to open

2
Japan cancels financing Matarbari coal project phase 2
Bangladesh

Japan cancels financing Matarbari coal project phase 2

3
Photo: TBS
Infrastructure

Gains from Padma Bridge to cross $10b, hope experts

4
Desco wanted to make a bold statement with their new head office building, a physical entity that would be a corporate icon. Photo: Courtesy
Habitat

Desco head office: When commitment to community and environment inspires architecture

5
Multiple robbery incidents reported in flood stranded Sylhet and Sunamganj
Bangladesh

Multiple robbery incidents reported in flood stranded Sylhet and Sunamganj

6
20 businesses get nod for $326m foreign loan for expansion
Economy

20 businesses get nod for $326m foreign loan for expansion

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
Workers unload wheat at Anu Mia Chowdhury Ghat at the outer anchorage of Chattogram port on the banks of River Karnaphuli on Thursday. Importers are importing large quantities of wheat from Canada, India, US, and Australia to meet the country’s food demand as imports of the essential commodity from Russia and Ukraine have been halted since the start of the Ukraine war. Photo: Mohammad Minhaj Uddin.

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net